clinical trials, cancer

Oncolytic viruses can help glioblastoma respond to immunotherapy.

Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.

At Brigham and Women’s Hospital, the cancer biologist is combining research into the tumor microenvironment with the principles of neuroscience to tease apart how cancers grow—and how to stop them.

A study reveals a molecular pathway linking exercise to an amped-up immune response to pancreatic cancer and greater responsiveness to treatment.

Because most people are vaccinated against tetanus as children, delivering benign bacteria carrying a tetanus antigen into pancreatic tumors makes them visible to memory cells in the immune system, researchers report.

First, the genetically engineered cells became CD8⁺ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4⁺ helper T cells that continue to circulate in his body.

An unfolded protein found in human milk shows promise in early clinical trials to treat bladder cancer.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

Calls to include a new breast cancer subtype in future clinical trials reveal fundamental disagreements about HER2’s role in the disease.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

Sensors encapsulated with oral chemotherapy drugs help patients and physicians keep track of treatments.

See how a computational pipeline uses next-generation sequencing data to identify genetic alterations that produce cancer-specific antigens.

The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.

Take a break from the bench to puzzle and peruse.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

US researchers could become the first outside China to use the gene-editing technique in the clinic. 

The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 

The publicly available database found nearly a third of samples included mutations targeted by either approved drugs or therapies in clinical trials.